Helius Medical Tech (NASDAQ: HSDT) reported second-quarter 2026 results that missed market expectations on both top-line and bottom-line metrics, even as the company advanced its strategic pivot from medical devices to digital asset treasury and infrastructure.

The company posted earnings per share (EPS) of $(0.38), missing the analyst consensus estimate of $(0.07) by 442.86 percent. This represents a significant deterioration compared to the prior year’s loss per share of $(79.73), though it marks a 99.52 percent improvement in the magnitude of losses year-over-year. On the revenue front, Helius Medical Tech reported sales of $2.5 million (specifically $2.526 million), falling short of the $3.6 million analyst estimate by 29.83 percent. However, this figure represents a substantial growth trajectory from the $43,000 recorded in the same period last year, a 5.77K percent increase driven primarily by staking rewards.

Strategic Shift and Operational Updates

The financial results reflect the company’s ongoing transition away from its legacy operations. Helius Medical Tech finalized the divestiture of its cash-consuming Point-of-Sale (PoNS) medical device business on April 8, 2026. This move removed ongoing costs associated with the non-core operation. Concurrently, the company acquired a Hong Kong-based regulated trust company for total consideration of $2 million, paid via a combination of 50% cash and 50% stock issuance. The transaction closed on July 15, 2026, and is expected to be reflected in third-quarter results. This acquisition aims to provide a licensed, in-region counterparty for institutional clients in Asia-Pacific.

Management highlighted several key operational milestones during the quarter:

• Launched its first institutional validator cluster in Tokyo, comprising three machines providing redundancy and an independent test environment.
• Secured its first third-party stake commitment of approximately 500,000 SOL, expected to generate revenue in Q3 2026.
• Delivered 15 institutional education sessions and advisory workshops with banks, asset managers, and exchanges across Asia-Pacific.
• Announced strategic partnerships with the Jito Foundation to expand institutional-grade Solana infrastructure and with Alatau City in Kazakhstan for blockchain infrastructure development.

Financial Performance and Capital Allocation

General and administrative expenses for the quarter totaled $11.1 million, up from $3.3 million in the prior year period. This increase was largely driven by the expansion of digital asset treasury operations and $6.8 million in severance costs associated with the PoNS divestiture. Of the $11.1 million G&A spend, approximately $6.8 million related to non-recurring items.

The company recorded an unrealized gain on digital assets of $2.4 million but also a realized loss of $25.4 million related to strategic sales executed as part of its capital allocation program. Net loss for the quarter stood at $30.3 million, or $(0.38) per share, based on weighted average shares outstanding of 79.8 million.

Despite the net loss, management continued its capital allocation strategy focused on maximizing SOL per share. During the quarter, Helius Medical Tech executed approximately $2.3 million in share repurchases, retiring 1.3 million shares. Year-to-date repurchases now total approximately $5.9 million. The company also completed a strategic institutional round of approximately $8 million led by Mirae Asset with participation from Ashke Capital.

As of June 30, 2026, Helius Medical Tech held approximately 2.3 million SOL across all categories, with a fair value of approximately $170.6 million. The company’s stock traded at a discount to net asset value (NAV), closing the quarter at approximately 0.81 times NAV, up from 0.73 times in the first quarter.

What the Numbers Show

The divergence between the year-over-year revenue growth and the miss against analyst estimates highlights the rapid scaling of Helius Medical Tech’s business from a negligible base ($43,000 to $2.5 million). While revenue has grown exponentially, it failed to meet the higher expectations set by analysts ($3.6 million). Simultaneously, while the EPS loss improved dramatically from $(79.73) to $(0.38) year-over-year, the company still widened its loss relative to the modest $(0.07) expected by the market for the current quarter. This suggests that operational efficiencies or cost controls did not align with the scaled-up revenue projections, partly due to the one-time severance costs and the investment phase of the new validator infrastructure.

The data indicates that while Helius Medical Tech is successfully expanding its top line through staking rewards, it has not yet reached the scale or profitability levels anticipated by investors for this quarter. The heavy reliance on staking revenue ($2.5 million of the $2.5 million total) underscores the transitional nature of the business model, with advisory and validator infrastructure revenues yet to materialize significantly.